CSIMarket
 
Proqr Therapeutics N v   (PRQR)
Other Ticker:  
 
 
Price: $2.5600 $0.24 10.345%
Day's High: $2.7 Week Perf: 26.73 %
Day's Low: $ 2.32 30 Day Perf: 32.64 %
Volume (M): 500 52 Wk High: $ 3.85
Volume (M$): $ 1,280 52 Wk Avg: $1.83
Open: $2.34 52 Wk Low: $1.11



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 100
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 106
 Capital Exp. (TTM) (Millions $) 2

Proqr Therapeutics N V
Proqr Therapeutics N.V. is a Dutch biotechnology company that specializes in the development of RNA therapies for the treatment of genetic disorders. The company was founded in 2012 and is headquartered in Leiden, the Netherlands.

The primary focus of Proqr Therapeutics is on the development of treatments for rare genetic disorders, which affects a relatively small number of people worldwide. Many of these disorders are caused by a single defective gene that leads to the production of a faulty protein, ultimately leading to disease.

Proqr Therapeutics develops RNA therapies that aim to correct or replace faulty genes, by targeting the RNA (ribonucleic acid) molecules that carry genetic information from DNA to the cells' protein-making machinery.

The company's lead candidate drug, sepofarsen (QR-110), is an RNA therapy being developed to treat a rare genetic disorder called Leber's congenital amaurosis type 10 (LCA10). This hereditary disease affects the retina, causing a progressive loss of vision, often leading to permanent blindness. Sepofarsen works by targeting the mRNA (messenger RNA) molecule that codes for the defective protein in LCA10, and thereby repairing the faulty gene.

Another RNA therapy in development by Proqr Therapeutics is called QR-421a, which targets a genetic mutation that causes Usher syndrome type 2a (USH2A), a progressive disease that causes both hearing and vision loss.

Proqr Therapeutics' RNA therapeutics are based on a proprietary platform technology called Axiomer, which enables the company to design and produce RNA molecules with specific properties that can target specific disease-causing genes.

In addition to its lead candidate drug, sepofarsen, and QR-421a, Proqr Therapeutics has several other RNA therapies in preclinical development for rare genetic diseases such as cystic fibrosis, Huntington's disease, and other genetic disorders that affect the central nervous system.

The company has collaborations with several academic institutions and pharmaceutical companies, including Allergan, Ionis Pharmaceuticals, and the Foundation Fighting Blindness.

Overall, Proqr Therapeutics N.V. is a biotech company that is leading the field of RNA therapies for the treatment of rare genetic disorders, with a focus on developing new treatments that can address the underlying genetic cause of disease.


   Company Address: Zernikedreef 9 Leiden 2333
   Company Phone Number: 88 166 7000   Stock Exchange / Ticker: NASDAQ PRQR
   PRQR is expected to report next financial results on March 28, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Proqr Therapeutics N V

ProQR Therapeutics NV reveals a shortcoming of $-0.39 per Share in fourth quarter of 2023

ProQR Therapeutics NV, a dedicated company focusing on revolutionizing RNA therapies using its proprietary Axiomer RNA editing technology platform, recently presented significant advancements at the 5th International Conference on Base Editing, Prime Editing & Related Enzymes (Deaminet 2024). The presentation showcased novel updates and breakthroughs that have the potential to impact ProQR's standing in the pharmaceutical industry.
ProQR Therapeutics NV presented at the prestigious conference held in San Diego, California. The presentation highlighted new platform data related to ProQR's Axiomer RNA editing technology. This technology is the company's proprietary platform for developing transformative RNA therapies. By utilizing Axiomer RNA editing technology, ProQR aims to correct or eliminate genetic errors that cause disease at the RNA level.

Announcement

title for the article:ProQR Highlights Groundbreaking Progress of Axiomer RNA Editing Technology at Deaminet 2024 Conference: Paving the Way for Transformative RNA Therapies

Published Fri, Jan 19 2024 12:00 PM UTC

ProQR Therapeutics NV, a dedicated company focusing on revolutionizing RNA therapies using its proprietary Axiomer RNA editing technology platform, recently presented significant advancements at the 5th International Conference on Base Editing, Prime Editing & Related Enzymes (Deaminet 2024). The presentation showcased novel updates and breakthroughs that have the potential ...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com